My name is Sejer Tobiasen. I'm a Director of the Executive Office, so I work very closely with Thomas Feldthus and the rest of the leadership team. Saniona is a clinical-stage biopharmaceutical company focused on developing dru gs for psychiatric and neurological diseases. Today, I'll explain a bit about why we believe Saniona is entering an important, but also very exciting new phase. Saniona is listed on Nasdaq Stockholm. We have a market cap of roughly SEK 1.5 billion. We have a very strong financial position with roughly SEK 0.5 billion in cash, after the end of Q2, and then roughly SEK 700 million for our planning purpose. That money comes primarily from our two most recent licensing deals. In 2024, we had our deal with Acadia, and in 2025, we had our deal with Jazz Pharmaceuticals. In both years, very profitable.
These two deals is a part of a very long track record. Our platform has been validated through multiple partnerships with leading pharmaceutical companies. You can see a list here on this side. Since 2012, Saniona has received roughly SEK 1.2 billion in milestone payments, and we could potentially receive SEK 19 million more from our ongoing partnerships. That demonstrates both the quality of our science, but also our ability to translate our discoveries into commercially attractive drug candidates and deals. It also puts us in a very exciting position, because these partnerships have now enabled us or given us the money to take our own programs further into clinical development, and this means Saniona and its shareholders essentially can keep a much larger share of the value. Today, we have two engines in CNS. On the top here, you see our two lead programs.
We have SAN2668, positioned for pediatric epilepsy, and then we have SAN2465, which is positioned for major depressive disorder, both of which are expected to initiate phase I around year-end. On the bottom half, you see the clinical partnerships that I alluded to on the previous slide. Here, these partnerships are being fully developed and paid by our partners, and you can see Acadia is planning to start a phase II in essential tremor. When that happens, we'll receive $10 million. Similarly, Jazz Pharmaceuticals is planning to start phase I. When that happens, we'll receive $7.5 million, and both of which are expected to happen next year. We also recently received our AstronauTx recently selected a clinical candidate that they have decided to move towards clinical development with from our research collaboration. Here, they are positioning it in REM sleep disorders and early Parkinson's.
Today, I'll focus on our two lead programs that you can see on this slide, and I'll start with SAN2668, which is positioned for pediatric epilepsy, or more specifically, DEE. This is a group of rare and very severe epilepsies in children. Most of these syndromes are rare, but together, it's roughly around 200,000 in the U.S. only. About three in five of the children with DEE, they become drug-resistant, meaning the available treatments today simply do not work well enough. The strongest medicines we have is benzodiazepines, and they are very potent, but they're typically reserved for hospitals or emergencies since children develop tolerances pretty quickly, and it's also very sedating, so you fall asleep. We also see seizure control is often not enough. These children with DEE, they struggle with a lot of different issues, especially learning and behavioral issues.
Many of these children never become independent, and ultimately, many of them are not able to feed themselves or even walk properly without support. It is very clear there is a significant unmet medical need, and we can also see that from the transactions ongoing in the space. in the top left corner here, you can see the recent deal with Jazz Pharmaceuticals that acquired Actio for $1.6 billion, and essentially for an early-stage epilepsy drug positioned in DEE. This is also how we see our lead asset, SAN2668. This compound, we have designed to provide benzodiazepine-strength seizure control, but without the sedation and tolerance that limits the use of these treatments. Ultimately, a drug that children can stay on.
We also aim to treat not only the seizures, but also the non-seizure burden, such as the cognition and behavioral issues that I alluded to before. In the preclinical, we have seen very strong results. We have seen strong efficacy across all the standard anti-seizure models in epilepsy. We have also seen good effect in the different genetic models of DEE, and then we see similar effect or seizure control to clobazam, which is one of the most used benzodiazepines today. It is important to note that we have seen all of this without any sign of sedation at the clinical relevant doses. Our strategy is to go for a broader DEE indication, as we expect this compound to work across multiple symptoms. It is similar to the strategy that Longboard used with bexicaserin before they were acquired by Lundbeck for $2.6 billion.
We also have an opportunity to accelerate our time to market if we focus on or have the opportunity to go for a single DEE syndrome that could give us an orphan drug designation and essentially make the regulatory process more efficient. This compound, as I mentioned, we are starting phase I, and then next year we also have an important opportunity for conducting a study in photosensitive epilepsy patients. That means we are able to get an early signal of effect in just a few patients, validating that the antiseizure efficacy we have seen in animals also translate into humans. If development goes as planned, this compound could be at a comparable stage to Actio already in 2028. Our second compound is positioned for a very different indication. Here we are positioning it for major depressive disorder.
There is more than 300 million that suffers from depression, and about a third of the patients with major depressive disorder are not helped with the current treatments available. They cycle through multiple treatments and end up with treatment-resistant depression. The traditional medicines, they often take weeks to work before they set in, so it also leaves patients waiting for much needed relief during a very critical period. The only fast option we have today is esketamine, but this compound requires two hours of monitoring in the clinic after every dose due to the side effects. Particularly, there is a high risk of abuse, but also dissociation, which is a feeling of being detached from yourself, known from ketamine. Similar to DEE, we see very strong transactions in this space. Recently, Lilly purchased a late-stage depression company for almost $3 billion.
Our second compound, SAN2465, we designed to produce a fast antidepressant effect, but without the liabilities such as dissociation and abuse potential. We also aim to address the cognitive impairment that the patients still struggle with even after their mood improve. In the preclinical studies, we have seen a rapid and sustained effect, particularly in depression-like symptoms such as anhedonia, anxiety, and cognition. We also recently demonstrated enhanced hippocampal synaptic plasticity in the form of LTP, providing further mechanistic support of this rapid antidepressant effect. We are a little bit ahead with this compound. Here we are, we just sent the IND application to the FDA in the middle of last month. Hopefully, if everything goes well, we will have the first human dose within this year. This was our two lead compounds.
Let me just wrap up with, let's say, four key points you can remember. First one, we have a validated CNS platform. Leading pharmaceutical companies have already invested substantially into our science. We have a fully owned upside. The two CNS programs that I alluded to are positioned in different indications where there is very attractive opportunities. Third, and probably most important and very privileged, is that we have a funded execution. Our cash position is expected to last into 2029, so beyond our initial important clinical readouts. Lastly, I think most important, or at least most exciting for me, is that we are approaching human validation. During next year, we will receive the first data on safety and target engagement.
For SAN2668, we also have this study in photosensitive epilepsy patients where we have the opportunity to demonstrate an early signal of effect. Saniona is transitioning from a company that has demonstrated its ability to create value through partnerships to one now that can create substantially more value through its own clinical development. Thank you.
Thank you. Do we have any questions in the room? Let's talk finances. Let's start there. What does the 10% issuance authorization from the EGM Monday mean?
Yes.
Does that indicate that you are planning to raise capital?
No. As I mentioned, we are at a very good state. We are not looking for short-term capital. Our runway is expected to extend into 2029. I think the mandate that the board have to issue shares is still very important. Of course, we always want to, let's say, raise capital at a position of strength. This just enables the board the ability to execute if there is an attractive opportunity or specialist investors that could be interested.
Got a question here about the depression track. Is it a U.S.-based phase I trial?
Yes. Yeah, so depression is in the U.S., and we submitted the, yeah, IND to the FDA. We are patiently waiting for clearance. Hopefully, they are halfway.
I was going to say, do you have any sense of the timeline, how long it will take?
FDA has one month.
Exactly.
That's basically it. I cannot do too anymore.
Halfway through that then. Yep.
Someone here is obviously more interested, wants to know more about SAN2465. Will there be an R&D day? Is there anything like that in the planning maybe that you, where you can tell more?
Yes. We had a webinar for SAN2668 that was very successful last year, or this year, sorry, a few months ago. We also plan to conduct this for 2465, but we plan this for Q1 2027, and primarily for two reasons. Now we're really focusing on getting our lead compounds into the clinic as fast and as smooth as possible. That requires some manpower. Then since this is early next year, we will also have the opportunity to speak a bit about the hopefully ongoing trial for the asset and bring in some KOLs that can allude more to positioning and the landscape.
I see. I think that's it. Thank you so much, Sejer.
Thank you very much.